Search
Fluspirilene
go.drugbank.com/drugs/DB04842ApprovedWithdrawnA long-acting injectable antipsychotic agent used for chronic schizophrenia.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesFebuxostat
go.drugbank.com/drugs/DB04854ApprovedInvestigationalFebuxostat is a non-purine xanthine oxidase (XO) inhibitor. In early 2008, febuxostat was granted marketing authorization by the European Commission for the treatment of chronic hyperuricemia and gout. In the following year, the FDA for ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesDexloxiglumide
go.drugbank.com/drugs/DB04856InvestigationalDexloxiglumide is a selective cholecystokinin type A (CCKA) receptor antagonist in phase III testing by Rottapharm in Europe only, as U.S. trials have been discontinued. As the D-isomer of loxiglumide, it retains all pharmacological prop...
Categories: Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C9 InhibitorsVoacamine
go.drugbank.com/drugs/DB04877ExperimentalVoacamine is an alkaloid isolated from the bark of the Pescheria fuchsiae folia tree. It is an antimalarial drug approved for use in several African countries. Voacamine is also under investigation for use in modulating multidrug-resista...
Categories: P-glycoprotein inhibitorsCalanolide A
go.drugbank.com/drugs/DB04886InvestigationalCalanolide A is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) derived from a plant found in the Malaysian rain forest. A related compound, calanolide B, also has anti-HIV activity. Both drugs are being developed by Sarawak...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesBicifadine
go.drugbank.com/drugs/DB04889InvestigationalBicifadine (DOV-220075) is a nonopioid analgesic. It is an inhibitor of both the norepinephrine and serotonin transporters and an NMDA antagonist with a non-narcotic profile. Bicifadine was shown to have potent analgesic activity in vivo...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesMilnacipran
go.drugbank.com/drugs/DB04896ApprovedInvestigationalMilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression . Furthermore...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsRifalazil
go.drugbank.com/drugs/DB04934InvestigationalRifalazil is a derivative of the antibiotic rifamycin. It is being investigated by ActivBiotics for the treatment of various bacterial infections.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesLofexidine
go.drugbank.com/drugs/DB04948ApprovedInvestigationalLofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesTipifarnib
go.drugbank.com/drugs/DB04960InvestigationalTipifarnib (R-115777) is a substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer. It belongs to the family of drugs called farnesyltransferase inhibitors. It is also called Zarnestra. ...
Categories: P-glycoprotein inhibitors